NICE approval of Linzagolix (Yselty) for Endometriosis

NICE approval of Linzagolix (Yselty) for Endometriosis

 

NICE approval of Linzagolix (Yselty) for Endometriosis is good news for women looking for effective treatment without hysterectomy.

There are far too few options available to treat endometriosis save for surgical removal of tissue or hysterectomy. We are pleased to see NICE approving this new medication for endometriosis.

Treatment is in conjunction with hormonal add back therapy (ABT, commonly known as hormone replacement therapy). Linzagolix with or without ABT has not been demonstrated to provide contraception. Women of
childbearing potential at risk of pregnancy have to use effective non-hormonal contraception while on treatment with Yselty.

Linzagolix is a gonadotrophin releasing hormone (GnRH) antagonist and works by supressing oestrogen inducing a ‘medical menopause’. This medication will not be appropriate for all but it is a good option until natural menopause occurs and symptoms naturally reduce.

It is similar to the GnRH antagonist Relugolix which was previously approved by NICE. However unlike Relugolix, Linzagolix does not contain add-back hormonal therapy which is to be taken separately. As with all menopause inducing medication, it is recommended that bone density is monitored.

 

Call us today

If you’re ready to discuss your situation or have any questions please contact Dr Victoria Handley today. Don’t suffer in silence. Call FREE on 0800 470 2009 or email vhandley@handleylaw.co.uk